<DOC>
	<DOCNO>NCT02787408</DOCNO>
	<brief_summary>The purpose study assess safety device performance Edwards Tricuspid Transcatheter Repair System patient clinically significant , symptomatic , tricuspid regurgitation high surgical risk standard tricuspid repair/replacement .</brief_summary>
	<brief_title>The SPACER Trial - Repair Tricuspid Valve Regurgitation Using Edwards TricuSPid TrAnsCatheter REpaiR System</brief_title>
	<detailed_description>The purpose study assess safety device performance Edwards Tricuspid Transcatheter Repair System patient clinically significant , symptomatic , tricuspid regurgitation high surgical risk standard tricuspid repair/replacement . The study multi-center , international , prospective , single arm , safety study . Enrolled subject assess clinical follow-up 1 month , 6 month , 1 year annually 3 year post implant procedure .</detailed_description>
	<mesh_term>Tricuspid Valve Insufficiency</mesh_term>
	<criteria>1 . Signed date Ethics Committee ( EC ) approve study consent form prior study related procedure 2 . Eighteen year age old 3 . Clinically significant , symptomatic ( New York Heart Association ( NYHA ) Functional Class II great ) , tricuspid regurgitation ( per applicable guideline ) require tricuspid valve repair replacement assess Heart Team 4 . Functional tricuspid regurgitation primary etiology 5 . New York Heart Association ( NYHA ) Functional Class II great sign persistent right heart failure despite optimal medical therapy 6 . Determined 'HEART Team ' ( minimum one Cardiologist , one Cardiac Surgeon ) high surgical risk tricuspid valve repair replacement benefitrisk analysis support utilization investigational device 7 . Willing attend study followup assessment 3 year Exclusion Criteria 1 . Tricuspid valve/right heart anatomy suitable study device : 1 . Native tricuspid annulus area &lt; 2.63 cm2 ( 12 mm device ) &lt; 3.27cm2 ( 15 mm device ) measure transthoracic echocardiography 2 . Subvalvular structures/anatomy would preclude proper anchor coaptation device placement , position retrieval 3 . Access pathway vessel diameter le 7.1 mm ( 12 mm device ) 8.3 mm ( 15 mm device ) 2 . Moderate great tricuspid valve stenosis 3 . Untreated clinically significant coronary artery disease require immediate revascularization 4 . Any therapeutic invasive cardiac procedure perform within 30 day schedule implant procedure 5 . Patients already receive dialysis renal insufficiency ( eGFR &lt; 25 ) per lab test ≤ 48 hour prior schedule implant procedure 6 . Myocardial infarction within 30 day schedule implant procedure 7 . Hemodynamic instability within 30 day schedule implant procedure 8 . Patient require surgery general anesthesia reason within 30 day schedule implant procedure 9 . Severe leave ventricular dysfunction ejection fraction &lt; 25 % within 45 day schedule implant procedure 10 . Patients pulmonary artery systolic pressure 2/3 systemic pressure via transthoracic echocardiography alternative standard modality ( e.g. , direct pressure measurement ) within 45 day 11 . Concomitant clinically significant valve ( aortic , mitral , pulmonic ) disease require immediate ( ± 30 day study procedure ) repair replacement 12 . Active endocarditis infection within 3 month schedule implant procedure 13 . Cerebrovascular accident within 3 month schedule implant procedure 14 . Noncardiac disease limit life expectancy le 12 month baseline evaluation 15 . Documented history bleed diathesis , coagulopathy gastrointestinal bleeding within 3 month schedule implant procedure 16 . Evidence right side intracardiac mass , thrombus , vegetation 17 . Prior venous stent place within access route ( e.g. , subclavian vein ) could negatively react device 18 . Previously treat tricuspid valve include implantation bioprosthetic valve mechanical valve 19 . Known hypersensitivity cobalt chromium , nitinol titanium 20 . Known hypersensitivity anticoagulation therapy contrast agent , adequately medicate 21 . Patient current intravenous drug user 22 . Female childbearing potential pregnant lactate 23 . Patient currently participate participate another investigational drug device clinical study within 30 day study screen activity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>